Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Cash from Investing Activities (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Cash from Investing Activities for 7 consecutive years, with $207.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities rose 422.91% year-over-year to $207.2 million, compared with a TTM value of -$38.0 million through Dec 2025, up 95.55%, and an annual FY2025 reading of -$38.0 million, up 95.55% over the prior year.
  • Cash from Investing Activities was $207.2 million for Q4 2025 at Avidity Biosciences, up from -$587.9 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $207.2 million in Q4 2025 and bottomed at -$587.9 million in Q3 2025.
  • Average Cash from Investing Activities over 5 years is -$64.7 million, with a median of -$12.7 million recorded in 2022.
  • Peak annual rise in Cash from Investing Activities hit 1466.5% in 2022, while the deepest fall reached 33323.81% in 2022.
  • Year by year, Cash from Investing Activities stood at -$84.1 million in 2021, then surged by 90.76% to -$7.8 million in 2022, then surged by 757.05% to $51.0 million in 2023, then plummeted by 225.73% to -$64.2 million in 2024, then soared by 422.91% to $207.2 million in 2025.
  • Business Quant data shows Cash from Investing Activities for RNA at $207.2 million in Q4 2025, -$587.9 million in Q3 2025, and $185.5 million in Q2 2025.